Literature DB >> 26283727

A Synthetic Lethal Interaction between Glutathione Synthesis and Mitochondrial Reactive Oxygen Species Provides a Tumor-Specific Vulnerability Dependent on STAT3.

Daniel J Garama1, Tiffany J Harris1, Christine L White1, Fernando J Rossello2, Maher Abdul-Hay3, Daniel J Gough4, David E Levy5.   

Abstract

Increased production of mitochondrion-derived reactive oxygen species (ROS) is characteristic of a metabolic shift observed during malignant transformation. While the exact sources and roles of ROS in tumorigenesis remain to be defined, it has become clear that maintaining redox balance is critical for cancer cell proliferation and survival and, as such, may represent a vulnerability that can be exploited therapeutically. STAT3, a latent cytosolic transcription factor activated by diverse cytokines and growth factors, has been shown to exhibit an additional, nontranscriptional function in mitochondria, including modulation of electron transport chain activity. In particular, malignant transformation by Ras oncogenes exploits mitochondrial STAT3 functions. We used mass spectrometry-based metabolomics profiling to explore the biochemical basis for the STAT3 dependence of Ras transformation. We identified the gamma-glutamyl cycle, the production of glutathione, and the regulation of ROS as a mitochondrion-STAT3-dependent pathway in Ras-transformed cells. Experimental inhibition of key enzymes in the glutathione cycle resulted in the depletion of glutathione, accumulation of ROS, oxidative DNA damage, and cell death in an oncogenic Ras- and mitochondrial STAT3-dependent manner. These data uncover a synthetic lethal interaction involving glutathione production and mitochondrial ROS regulation in Ras-transformed cells that is governed by mitochondrial STAT3 and might be exploited therapeutically.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26283727      PMCID: PMC4589592          DOI: 10.1128/MCB.00541-15

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  49 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  Objective antitumor activity of acivicin in patients with recurrent CNS malignancies: a Southwest Oncology Group trial.

Authors:  S A Taylor; J Crowley; T W Pollock; H J Eyre; C Jaeckle; H E Hynes; R L Stephens
Journal:  J Clin Oncol       Date:  1991-08       Impact factor: 44.544

3.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

4.  Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis.

Authors:  O W Griffith
Journal:  J Biol Chem       Date:  1982-11-25       Impact factor: 5.157

5.  Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity.

Authors:  Frank Weinberg; Robert Hamanaka; William W Wheaton; Samuel Weinberg; Joy Joseph; Marcos Lopez; Balaraman Kalyanaraman; Gökhan M Mutlu; G R Scott Budinger; Navdeep S Chandel
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-26       Impact factor: 11.205

6.  Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.

Authors:  Anuhar Chaturvedi; Michelle Maria Araujo Cruz; Nidhi Jyotsana; Amit Sharma; Haiyang Yun; Kerstin Görlich; Martin Wichmann; Adrian Schwarzer; Matthias Preller; Felicitas Thol; Johann Meyer; Reinhard Haemmerle; Eduard A Struys; Erwin E Jansen; Ute Modlich; Zhixiong Li; Laura M Sly; Robert Geffers; Robert Lindner; Dietmar J Manstein; Ulrich Lehmann; Jürgen Krauter; Arnold Ganser; Michael Heuser
Journal:  Blood       Date:  2013-08-16       Impact factor: 22.113

7.  Phase I study of acivicin and cisplatin in non-small-cell lung cancer. A National Cancer Institute of Canada study.

Authors:  J A Maroun; D J Stewart; S Verma; W K Evans; E Eisenhauer
Journal:  Am J Clin Oncol       Date:  1990-10       Impact factor: 2.339

Review 8.  Ras, superoxide and signal transduction.

Authors:  K Irani; P J Goldschmidt-Clermont
Journal:  Biochem Pharmacol       Date:  1998-05-01       Impact factor: 5.858

9.  Phase II trial of acivicin versus etoposide-cisplatin in non-small cell lung cancer. An Eastern Cooperative Oncology Group study.

Authors:  P Bonomi; D Finkelstein; A Chang
Journal:  Am J Clin Oncol       Date:  1994-06       Impact factor: 2.339

10.  Essential role of STAT3 in postnatal survival and growth revealed by mice lacking STAT3 serine 727 phosphorylation.

Authors:  Yuhong Shen; Karni Schlessinger; Xuejun Zhu; Eric Meffre; Fred Quimby; David E Levy; J E Darnell
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

View more
  20 in total

Review 1.  Human hyper-IgE syndrome: singular or plural?

Authors:  Qian Zhang; Bertrand Boisson; Vivien Béziat; Anne Puel; Jean-Laurent Casanova
Journal:  Mamm Genome       Date:  2018-08-09       Impact factor: 2.957

2.  Effective demethylation of melanoma cells using terahertz radiation.

Authors:  Hwayeong Cheon; Hee-Jin Yang; Moran Choi; Joo-Hiuk Son
Journal:  Biomed Opt Express       Date:  2019-09-05       Impact factor: 3.732

3.  Stress-induced dynamic regulation of mitochondrial STAT3 and its association with cyclophilin D reduce mitochondrial ROS production.

Authors:  Jeremy A Meier; Moonjung Hyun; Marc Cantwell; Ali Raza; Claudia Mertens; Vidisha Raje; Jennifer Sisler; Erin Tracy; Sylvia Torres-Odio; Suzana Gispert; Peter E Shaw; Heinz Baumann; Dipankar Bandyopadhyay; Kazuaki Takabe; Andrew C Larner
Journal:  Sci Signal       Date:  2017-03-28       Impact factor: 8.192

4.  Mitochondrial STAT3 is negatively regulated by SOCS3 and upregulated after spinal cord injury.

Authors:  Keun Woo Park; Ching-Yi Lin; Etty N Benveniste; Yu-Shang Lee
Journal:  Exp Neurol       Date:  2016-08-05       Impact factor: 5.330

Review 5.  STAT3 signaling in immunity.

Authors:  Emily J Hillmer; Huiyuan Zhang; Haiyan S Li; Stephanie S Watowich
Journal:  Cytokine Growth Factor Rev       Date:  2016-05-09       Impact factor: 7.638

Review 6.  Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.

Authors:  Uddalak Bharadwaj; Moses M Kasembeli; Prema Robinson; David J Tweardy
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

7.  Novel STAT3 small-molecule inhibitors identified by structure-based virtual ligand screening incorporating SH2 domain flexibility.

Authors:  Ren Kong; Uddalak Bharadwaj; T Kris Eckols; Mikhail Kolosov; Haoyi Wu; Francisco J Santa Cruz-Pavlovich; Alison Shaw; Oluwatomilona I Ifelayo; Hong Zhao; Moses M Kasembeli; Stephen T C Wong; David J Tweardy
Journal:  Pharmacol Res       Date:  2021-04-29       Impact factor: 10.334

Review 8.  Mitochondrial Stat3, the Need for Design Thinking.

Authors:  Rui Yang; Mercedes Rincon
Journal:  Int J Biol Sci       Date:  2016-02-29       Impact factor: 6.580

9.  Oxidative Stress Activated by Sorafenib Alters the Temozolomide Sensitivity of Human Glioma Cells Through Autophagy and JAK2/STAT3-AIF Axis.

Authors:  Jianwei Wei; Zhengfeng Wang; Weiwei Wang; Xiaoge Liu; Junhu Wan; Yongjie Yuan; Xueyuan Li; Liwei Ma; Xianzhi Liu
Journal:  Front Cell Dev Biol       Date:  2021-06-14

Review 10.  Fundamentals of cancer metabolism.

Authors:  Ralph J DeBerardinis; Navdeep S Chandel
Journal:  Sci Adv       Date:  2016-05-27       Impact factor: 14.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.